Diversified healthcare company UnitedHealth Group (NYSE: UNH) reported higher earnings and revenues for the second quarter of 2023. The company also raised
Infographic: Highlights of UnitedHealth Group’s (UNH) Q2 2023 earnings
Categories
Biotechnology
Ocean Biomedical focuses its malaria program to address chronic malaria crisis in sub-Saharan Africa
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it is focusing its multi-pronged malaria program to address the chronic malaria
Apogee Therapeutics set to go public. Here’s what you need to know
The US IPO market has remained mostly sluggish so far this year, continuing the weakness experienced in 2022. Meanwhile, there is speculation
Ocean Biomedical (OCEA) joins the Russell 2000 Index
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has been included in the Russell 2000 Index and the broad-market Russell 3000
Ocean Biomedical granted US patent for bispecific cancer immunotherapy treatment
Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Monday said its scientific co-founder Dr. Jack Elias has been granted a new, broad
Ocean Biomedical extends patent rights for idiopathic pulmonary fibrosis discovery to Europe
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Friday revealed that its scientific co-founder Dr. Jack Elias has received notice from the
Walgreens Boots Alliance (WBA) set to report Q3 results. What’s in the cards
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), a leading retailer and wholesaler of health and wellness products, is scheduled to report third-quarter earnings
Avid Bioservices Inc. (CDMO) Q4 2023 Earnings Call Transcript
Avid Bioservices Inc. (NASDAQ: CDMO) Q4 2023 earnings call dated Jun. 21, 2023 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President and Chief
Fundamental Research Corp. raises Ocean Biomedical’s price target to $17.63 per share
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Wednesday said that Fundamental Research Corp. increased the price target of the company’s stock to $17.63
Earnings Summary: A snapshot of Catalent’s Q3 2023 results
Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the third
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific
Taglich Brothers initiates coverage of Ocean Biomedical, with price target of $20
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday revealed that Taglich Brothers initiated coverage on the company with a share price
Ocean Biomedical (OCEA) set to join the Russell 2000 Index
Biopharmaceutical company Ocean Biomedical (NASDAQ: OCEA) on Thursday said it is expected to be added to the Russell 2000 Index, effective after
Ocean Biomedical (OCEA) announces patent award for novel cancer immunotherapy treatment
Biopharma company Ocean Biomedical (NASDAQ: OCEA) on Tuesday said its scientific co-founder Dr. Jack Elias has been issued a broad patent for
Ocean Biomedical announces private placement of $25 mln convertible notes
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has entered into a private placement pursuant to a securities purchase
Earnings: Regeneron Pharmaceuticals (REGN) Q1 profit falls; revenue up 7%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported a decline in adjusted earnings for the first quarter of 2023, despite an increase
Corcept Therapeutics Incorporated (CORT) Q1 2023 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ: CORT) Q1 2023 Earnings Call dated May. 03, 2023 Corporate participants: Atabak Mokari -- Chief Financial Officer Charlie
A snapshot of AmerisourceBergen’s Q2 2023 earnings results
Pharmaceutical solutions provider AmerisourceBergen Corporation (NYSE: ABC) reported higher revenues and adjusted earnings for the second quarter of 2023. Second-quarter revenue increased
VRTX Earnings: A snapshot of Vertex Pharmaceuticals’ Q1 2023 results
Healthcare firm Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on Monday reported a decline in adjusted earnings for the first quarter, despite an increase in
Trxade Health Inc. (NASDAQ: MEDS) Q1 2023 Research Summary
Trxade Health Inc. (NASDAQ: MEDS) is a healthcare IT company that operates as an integrated drug procurement and delivery platform. It is
AMGN Earnings: Everything you need to know about Amgen’s Q1 results
Amgen Inc. (NASDAQ: AMGN) has reported lower revenues and adjusted earnings for the first quarter of 2023. The biotechnology firm also provided